Akari Therapeutics (AKTX) Income from Continuing Operations (2014 - 2026)

Akari Therapeutics has disclosed Income from Continuing Operations across 9 years of filings, most recently posting 14455000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 14455000.0, down 290.15% year-over-year; the trailing twelve-month figure through Mar 2026 was 29322000.0 (down 64.09% YoY), and the FY2025 annual result was 17298000.0, up 12.6% from the prior year.
• Income from Continuing Operations came in at 14455000.0 for Q1 2026 at Akari Therapeutics, down from 5298000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 2491000.0 in Q3 2023 to a low of 14455000.0 in Q1 2026.
• The 4-year median for Income from Continuing Operations is 4586000.0 (2023), against an average of 5377153.85.
• Across the five-year window, Income from Continuing Operations soared 57.74% in 2025 and plunged 290.15% in 2026, its largest moves.
• Akari Therapeutics' Income from Continuing Operations stood at 5083000.0 in 2023, then advanced by 25.79% to 3772000.0 in 2024, then slumped by 40.46% to 5298000.0 in 2025, then tumbled by 172.84% to 14455000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 14455000.0 (Q1 2026), 5298000.0 (Q4 2025), and 6400000.0 (Q3 2025), per Business Quant data.